BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mathew S, Faheem M, Hassain NA, Benslimane FM, Thani AAA, Zaraket H, Yassine HM. Platforms Exploited for SARS-CoV-2 Vaccine Development. Vaccines (Basel) 2020;9:11. [PMID: 33375677 DOI: 10.3390/vaccines9010011] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Abdolmaleki G, Taheri MA, Paridehpour S, Mohammadi NM, Tabatabaei YA, Mousavi T, Amin M. A comparison between SARS-CoV-1 and SARS-CoV2: an update on current COVID-19 vaccines. DARU J Pharm Sci 2022. [DOI: 10.1007/s40199-022-00446-8] [Reference Citation Analysis]
2 Leekha A, Saeedi A, Sefat SR, Kumar M, Martinez-paniagua M, Damian A, Kulkarni R, Rezvan A, Mosoumi S, Liu X, Cooper LJ, Sebastian M, Hurst B, Varadarajan N. Ending transmission of SARS-CoV-2: sterilizing immunity using an intranasal subunit vaccine.. [DOI: 10.1101/2022.07.14.500068] [Reference Citation Analysis]
3 Muhar BK, Nehira J, Malhotra A, Kotchoni SO. The Race for COVID-19 Vaccines: The Various Types and Their Strengths and Weaknesses. J Pharm Pract 2022;:8971900221097248. [PMID: 35723017 DOI: 10.1177/08971900221097248] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Mardian Y, Shaw-shaliba K, Karyana M, Lau C. Sharia (Islamic Law) Perspectives of COVID-19 Vaccines. Front Trop Dis 2021;2:788188. [DOI: 10.3389/fitd.2021.788188] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
5 Fakhroo A, AlKhatib HA, Al Thani AA, Yassine HM. Reinfections in COVID-19 Patients: Impact of Virus Genetic Variability and Host Immunity. Vaccines (Basel) 2021;9:1168. [PMID: 34696276 DOI: 10.3390/vaccines9101168] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
6 Wehbe Z, Wehbe M, Iratni R, Pintus G, Zaraket H, Yassine HM, Eid AH. Repurposing Ivermectin for COVID-19: Molecular Aspects and Therapeutic Possibilities. Front Immunol 2021;12:663586. [PMID: 33859652 DOI: 10.3389/fimmu.2021.663586] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 17.0] [Reference Citation Analysis]
7 Loo KY, Letchumanan V, Ser HL, Teoh SL, Law JW, Tan LT, Ab Mutalib NS, Chan KG, Lee LH. COVID-19: Insights into Potential Vaccines. Microorganisms 2021;9:605. [PMID: 33804162 DOI: 10.3390/microorganisms9030605] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 21.0] [Reference Citation Analysis]
8 Blasi F, Gramegna A, Sotgiu G, Saderi L, Voza A, Aliberti S, Amati F. SARS-CoV-2 vaccines: A critical perspective through efficacy data and barriers to herd immunity. Respir Med 2021;180:106355. [PMID: 33721697 DOI: 10.1016/j.rmed.2021.106355] [Cited by in Crossref: 13] [Cited by in F6Publishing: 18] [Article Influence: 13.0] [Reference Citation Analysis]
9 Yoo JH. What We Do Know and Do Not Yet Know about COVID-19 Vaccines as of the Beginning of the Year 2021. J Korean Med Sci 2021;36:e54. [PMID: 33559409 DOI: 10.3346/jkms.2021.36.e54] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 20.0] [Reference Citation Analysis]
10 Tulay P, Ergoren MC, Dundar M. COVID-19 vaccines: Where do we stand? The EuroBiotech Journal 2021;5:4-7. [DOI: 10.2478/ebtj-2021-0002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]